Markets:

Overview

News

Currencies

International

Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

102.08 -0.06 (-0.05%)

Streaming Delayed Price Updated: 9:49 AM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Detecting Early Cancer Screening Stocks At An Early Stage Is Critical ↗

November 22, 2021

If you're going to get cancer, you’re going to want to detect it early. While we’ve come a long way, baby, when it comes to treating terrible maladies like lung...

Via Benzinga

The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares ↗

November 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded...

Via Benzinga

Study Shows Guardant360® Liquid Biopsy Test Helps Guide Treatment for Patients with HER2-Driven Metastatic Colorectal Cancer

November 11, 2021

From Guardant Health, Inc.

Via Business Wire

Earlier Screening and Aging Population Driving Surging Growth in Colorectal Diagnostics Demand

November 11, 2021

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – November 11, 2021 – New recommendations for colorectal cancer (CRC) screening by both the US Preventative Services Task Force...

Via FinancialNewsMedia

Guardant Health to Participate in the 2021 Stifel Healthcare Conference

November 08, 2021

From Guardant Health, Inc.

Via Business Wire

Guardant Health Registers 27% Revenue Growth In Q3, Tops Consensus; Backs FY21 Guidance ↗

November 05, 2021

Guardant Health Inc (NASDAQ: GH) reported Q3 sales of $94.8 million, +27% Y/Y, beating the Wall Street estimate of $92.64 million. Guardant's Q3 precision oncology...

Via Benzinga

Guardant Health Inc (GH) Q3 2021 Earnings Call Transcript ↗

November 05, 2021

GH earnings call for the period ending October 30, 2021.

Via The Motley Fool

Topics Earnings

Guardant Health: Q3 Earnings Insights ↗

November 04, 2021

Guardant Health (NASDAQ:GH) reported its Q3 earnings results on Thursday, November 4, 2021 at 04:03 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Guardant Health Reports Third Quarter 2021 Financial Results

November 04, 2021

From Guardant Health, Inc.

Via Business Wire

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗

November 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...

Via Benzinga

Guardant Health and The Royal Marsden NHS Foundation Trust Announce Partnership to Establish First Guardant Health Liquid Biopsy Testing Service Based in the United Kingdom

November 03, 2021

From Guardant Health, Inc.

Via Business Wire

Data Presented at ACG Shows Guardant Health’s Blood-Based Test Accurately Detects Early-Stage Colorectal Cancer

October 25, 2021

From Guardant Health, Inc.

Via Business Wire

Guardant Health Appoints Myrtle Potter to Its Board of Directors

October 20, 2021

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Report Third Quarter Financial Results on November 4, 2021

October 08, 2021

From Guardant Health, Inc.

Via Business Wire

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal™ Blood Test to Predict Recurrence Across Early-Stage Cancers

October 05, 2021

From Guardant Health, Inc.

Via Business Wire

Guardant Health Will Not Go With NeoGenomics Deal: Bloomberg ↗

October 04, 2021

Guardant Health Inc (NASDAQ: GH) has decided not to pursue a potential acquisition of NeoGenomics Inc (NASDAQ: NEO), Bloomberg reported citing people...

Via Benzinga

54 Biggest Movers From Friday ↗

October 04, 2021

Check out these big penny stock gainers and losers Losers Spire Global, Inc.. (NYSE: SPIR) shares fell 43.3% to close at $7.10 on Friday. Spire Global, Inc....

Via Benzinga

Why Guardant Health Is Down More Than 14% Friday ↗

October 01, 2021

Investors aren't fans of an acquisition the diagnostics company is rumored to be considering.

Via The Motley Fool

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 01, 2021

Gainers Biomerica (NASDAQ:BMRA) stock moved upwards by 39.33% to $6.27 during Friday's regular session. As of 12:30 EST, Biomerica's stock is trading at a volume...

Via Benzinga

Guardant Health Weighing NeoGenomics Acquisition: Bloomberg ↗

October 01, 2021

Bloomberg reported that Guardant Health Inc (NASDAQ: GH) is reportedly exploring an acquisition of NeoGenomics Inc (NASDAQ: NEO), citing people familiar...

Via Benzinga

Investing in These 2 Top Stocks Could Make You a Millionaire Retiree ↗

September 30, 2021

Both of these companies boast exciting growth prospects.

Via The Motley Fool

Topics Retirement

Guardant Health Showcases Data at ESMO 2021 Demonstrating Utility of Guardant360® Liquid Biopsy to Obtain Comprehensive Molecular Information to Guide Targeted Therapy Options for Late-Stage Cancers

September 15, 2021

From Guardant Health, Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

September 10, 2021

Gainers Hepion Pharmaceuticals (NASDAQ:HEPA

Via Benzinga

Return on Capital Employed Insights for Guardant Health ↗

September 01, 2021

After pulling data from Benzinga Pro it seems like during Q2, Guardant Health's (NASDAQ:GH) reported sales totaled $92.10 million. Despite a 9.48% in earnings, the company posted...

Via Benzinga

Guardant Health Expands Precision Oncology Offerings ↗

August 11, 2021

Guardant’s Q2 revenues grew 39% over the year to $92.1 million, ahead of the Street’s forecast by 8.8%. On an adjusted basis, it reported a loss of $0.96 per share, falling below the Street’s estimates...

Via Talk Markets

Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit

August 06, 2021

From Guardant Health, Inc.

Via Business Wire

Guardant Health, inc (GH) Q2 2021 Earnings Call Transcript ↗

August 06, 2021

GH earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Precision Oncology Sales Boost Guardant Health Q2 Topline, Backs FY21 Outlook, Management Updates ↗

August 06, 2021

After the market close on Thursday, Guardant Health Inc (NASDAQ: GH) reported Q2 revenues increased 39% Y/Y to $92.1 million, beating the consensus of $84.61...

Via Benzinga

The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO ↗

August 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)...

Via Benzinga

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.